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1 Brigham and Women's Hospital, Boston, Mass; 2 Harvard School of Public Health, Boston, Mass Objectives: Benefit from asymptomatic carotid endarterectomy (AsCEA) depends on long-term survival. We undertook this study to examine 5-year survival (5-ys) in octogenarians after AsCEA.
Methods: National Medicare data from 2006-2011 was used to examine 5-ys in patients aged $80 who underwent elective AsCEA in 2006 without evidence of TIA or stroke 180 days before surgery. We calculated overall mortality and used Kaplan-Meier curves to examine 5-ys. We built Cox proportional hazards (CPH) models to examine the independent predictors of survival after AsCEA.
Results: In 2006 16,616 patients aged $80 years underwent AsCEA; 1.3% died #30 days of surgery. Overall, the probability of 5-ys was 0.56 (95% confidence interval [CI] , 0.55-0.57). A multivariate CPH model identified the following comorbidities (COM) as having a significant effect on 5-ys (hazard ratio, 95% CI): COPD (1.45, 1.37-1.53), CHF (1.90, 1.78-2.03), diabetes (1.10, 1.04-1.16), renal failure (1.74, 1.62-1.86), and valve disease (1.23, 1.15-1.32). Age and COM both affected 5-ys, with the probability of survival ranging from 0.71 (95% CI, 0.69-0.74) for an 80-year-old (yo) with no COM to 0.18 (95% CI, 0.04-0.38) for a $85-yo with three COM (P < .01. Conversely, a $85-yo with no COM had survival superior to an 80-yo with three COM (0.53 [95% CI, 0.51-0.55] vs 0.34 [95% CI, 0.23-0.45]; P < .01) (Table) .
Conclusions: Although AsCEA may be appropriate for some older Americans, this study demonstrates that many octogenarians do not live long enough to derive benefit. Careful selection is essential.
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Methods: Patients included underwent consecutive CEAs (2009) (2010) (2011) (2012) (2013) for symptomatic carotid stenosis $60%. They had a National Institutes of Health Stroke Scale (NIHSS) score <5 on presentation. Patients were divided according to time between the qualifying event and surgery (0-14 days, n ¼ 100: early CEA; 15-30 days, n ¼ 222: delayed CEA). Outcomes were death, stroke, myocardial infarct (MI), 30-day major adverse event (MAE) rate (composite of stroke, death, and MI), and NI defined as a NIHSS score decrease ($1) rate at 30 days. Independent neurologic assessment was performed.
Results: Type of qualifying symptoms (stroke vs transient ischemic attack) was similar. Early CEA patients had a higher American Society of Anesthesiologists physical status risk (P ¼ .0001) and were more under dual antiplatelet therapy (P ¼ .02). Outcomes are summarized in the Table. Thirty-day NI was associated with early CEA (odds ratio, 1.9; 95% confidence interval, 1.0-3.7; P ¼ .03).
Conclusions: Our results suggest that reducing the time for intervention in selected (NIHSS <5) and stable symptomatic patients is safe and associated with neurologic status improvement at 30 days. Objectives: Recently we defined several independent high-risk criteria that were inclusive and exclusive of the SAPPHIRE (Stenting with Angioplasty and Protection in Patients at High Risk for Endarterectomy) trial. The objective of this study was to create a risk index that may predict patients at high risk for carotid endarterectomy (CEA).
Methods: Data on 3,098 CEAs between 2003 and 2011 at 20 Vascular Study Group of New England (VSGNE) centers were used for this study. SAPPHIRE general inclusion criteria and primary outcomes of death, stroke, or myocardial infarction were used, as were other previously reported high-risk criteria. Factors that were associated with the primary outcome by analysis of variance (P < .10) and not linearly dependent, as determined by a Pearson's correlation analysis, were further assessed for an independent association by multivariate logistic regression. A risk index model was developed for these significant predictors using an integer score as a reliable formula.
Results: Multivariate analysis (P < .05) found the following independently significant risk factors (95% confidence interval): age in years (1.0-1.1; P < .001), preadmission nursing home (1.2-6.6; P ¼ .020), congestive heart failure (CHF; 1.4-2.8; P < .001), diabetes (1.1-1.3; P < .001), chronic obstructive pulmonary disease (COPD; 1.2-1.5; P < .001), any previous cerebrovascular disease (CVD; 1.1-1.9; P ¼ .003), and contralateral internal carotid artery stenosis (1.0-1.2; P ¼ .001). The predictors are age in years (40-49: 0 points; 50-59: 2 points; 60-69: 4 points; 70-79: 6 points; 80-89: 8 points), living in a nursing home (4 points), any CVD (2 points), CHF (5 points), COPD (3 points), diabetes (2 points), degree of contralateral stenosis (<50%: 0 points; 50-69%: 1 point; 70-near occlusion: 2 points; occlusion: 3 points). Lowestrisk CEA was defined as 0 points with an estimated risk of 2.7%, highest-risk CEA was defined as >13 points, representing adverse outcome rate of 22.5%.
Conclusions: The SAPPHIRE high-risk CEA definition is not accurate. We propose a new, evidence-based definition of high-risk CEA. The CEA risk index model may assist clinicians in appropriate patient selection. Future studies should aim at validation of this risk index model. Baseline characteristics were compared, and propensity scores were calculated with a logistic regression model that adjusted for clinical differences. Thirty-day mortality and adverse neurologic event rates as well as 4-year survival and ischemic stroke rates were analyzed in populations matched by gender and procedure.
Results: There were 10,399 women and 13,765 men with CEA and 1,421 women and 1,946 men with CAS. In unmatched populations, CAS compared with CEA was associated with more 30-day neurologic events for both women (3.3% vs 2.4%; P ¼ .012) and men (4.1% vs 2.9%; P ¼ .011). This difference persisted in matched populations. There was no difference in 30-day mortality with or without matching. When compared with CEA during 4 years of follow-up, unmatched patients after CAS had inferior overall survival irrespective of whether they were female (79.3% vs 82.8%; P ¼ .006) or male (74.7% vs 80.5%; P < .001). Men compared with women experienced worse survival after CAS (P ¼ .006) or CEA (P < .001). However, after CEA, women at 4 years had higher ischemic stroke rates than men (4.6% vs 3.3%; P < .001) but similar rates of ischemic strokes after CAS. These gender differences persisted in matched populations. After matching, CEA vs CAS patients experienced fewer ischemic strokes among men (3.6% vs 4.4%; P ¼ .044), but not among women.
Conclusions: CAS compared with CEA patients had worse long-term survival in both genders and more ischemic strokes in men. Women had better survival regardless of procedure, whereas men with CEA had less ischemic strokes over 4 years. These results should be taken into account during counseling for carotid intervention.
